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To assist international efforts to address major gaps in the availability and accessibility of quality diagnosis and treatment for multi-
drug resistant tuberculosis, Médecins Sans Frontières has adapted an approach combining three sets of interlinked strategies: direct 
provision of medical care, operational research, and public health advocacy. The activities undertaken are reviewed each in turn, with 
stress on the ways that they impact upon and consolidate each other. In spite of new opportunities, including technologies which 
significantly improve diagnosis and new, more patient-centred approaches, a much broader international mobilization is needed in 
order to confront MDR-TB. It is also questionable as to whether existing technologies are successful enough to provide a solid basis 
for expanded national programs.
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background
The major gaps that exist in the availability and acces-
sibility of quality diagnosis and treatment of multidrug-
resistant tuberculosis (MDR-TB) are some of the impor-
tant drivers of the epidemic of this disease. Fewer than 
5% of new and previously treated TB patients were tested 
for drug resistance in 2010 [1]. Only 10% of the estimated 
caseload of MDR-TB patients among notified TB cases 
in 2009 had access to treatment [2]. Drug-resistant TB is 
especially prevalent in the countries of the former Soviet 
Union: the nine countries with MDR-TB rates in new TB 
cases higher than 12% are all former Soviet countries [3]. 
There are 31,914 total confirmed cases of MDR-TB in the 
former Soviet countries [4].
Commitment by governments and the international 
public health community to tackling the MDR-TB epi-
demic appears to be growing. In the Berlin Declaration 
of 2007 [5], ministers of member states in the WHO 
European region committed to concerted action to im-
plement the Stop TB Strategy [6]. The Beijing Call to 
Action of 2009 [7] was issued by WHO member states 
affected by M/XDR-TB (extensively drug-resistant TB) 
that resulted in a World Health Assembly resolution on 
the prevention and control of these forms of TB [8]. Gov-
ernments committed to “moving urgently towards uni-
versal access of diagnosis and treatment of M/XDR-TB 
by 2015,” including through the introduction of a com-
prehensive approach incorporating improved diagnosis 
systems and infection control policies, proper adherence 
to treatment protocols, improved drug supply and sus-
tainable financing and human resourcing.
The role of Médecins Sans Frontières
For Médecins Sans Frontières (MSF), a non-govern-
mental medical-humanitarian association, the primary 
response to the MDR-TB epidemic in the countries of 
the former Soviet Union is through direct provision of 
quality diagnosis and treatment to patients. MSF has 
been involved in the diagnosis and treatment of MDR-
TB in the former Soviet countries for more than a dec-
ade and was a founder of the Green Light Committee, 
which supports countries in the management of MDR-
TB. Using the experience from these activities, MSF 
decided to address the wider efforts being undertaken 
by governments in the region and by other international 
public health institutions in the hope of assisting the 
development of a larger response. MSF’s approach to 
MDR-TB treatment in the former Soviet countries has 
three components (Box 1).European Journal of Microbiology and Immunology 2 (2012) 4
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msf’s medical Programs
Location and history
MSF is providing diagnosis and treatment for MDR-TB 
patients in six countries: Armenia, Georgia, Kyrgyzstan, 
the Russian Federation, Tajikistan, and Uzbekistan. 
A program is soon to start in Ukraine. The longest-run-
ning continuous TB program started in Uzbekistan in 
1998 and began treating MDR-TB in 2001. Two new pro-
grams were initiated in 2011, in Tajikistan and the Kara 
Suu district of southern Kyrgyzstan. The largest program, 
in terms of expenditures, staff and patient numbers, is 
in Karakalpakstan in Uzbekistan with 869 patients with 
drug-resistant TB and 228 with drug-susceptible TB in 
treatment on May 31, 2012. At the end of 2011, MSF was 
treating approximately 1500 patients for tuberculosis in 
the former Soviet Union.
Patient-centred model of care
MSF’s model of care is based on a comprehensive and 
patient-centred approach: diagnosing and treating all 
cases; and addressing the high default rates common 
with MDR-TB treatment (Box 2). A strong focus has 
been the introduction of high-quality laboratories with 
rapid drug-susceptibility testing to enable the rapid ini-
tiation of correct treatment. Also, heavily emphasized is 
ambulatory treatment, if possible from the first day, in 
order to lower default rates by bringing treatment closer 
to where the patient lives and reduce the chance of no-
socomial transmission of drug resistance. All programs 
are carried out jointly with the Ministry of Health in-
side public facilities.
Responding to research data
MSF’s programatic approach has varied and developed 
with experience and new data. For example, the program 
in Uzbekistan initially focussed on DOTS implementa-
tion. In 2003, a drug susceptibility study found high levels 
of drug resistance, leading to the initiation of a DOTS-
Plus program, treating only drug-resistant forms of the 
disease. While outcomes were acceptable, it became 
clear that drug resistance was becoming more prevalent, 
caused in part by the inappropriate treatment of drug-sus-
ceptible cases. In response, in 2010, MSF and the Minis-
try of Health initiated a comprehensive program with the 
aim of improving the cohesiveness of the program, and 
in particular the early diagnosis and treatment of MDR-
TB in the Republic of Karakalpakstan. A study on the 
amplification of MDR-TB into XDR-TB led to greater 
concentration on, and improvements in, infection control 
[9]. A study of community-based care in South Africa 
has modified the approach towards decentralising care in 
Karakalpakstan [10].
Direct provision of diagnosis and treatment, including through the application of new technologies and new approaches
Operational research to assess and promote models of care, new technologies and innovations
Public health advocacy, aimed at regional governments and international organisations to bring about positive changes in existing 
health systems and also at the pharmaceutical industry and research community to bring into being new technologies to improve 
control efforts
box 1. MSF’s approach to MDR-TB treatment in the former Soviet countries
diagnosis: Rapid diagnosis of TB and drug susceptibility testing
treatment:
  – Comprehensive – drug-susceptible and drug-resistant TB 
  – Decentralised – preference for community based treatment, even from day 1
  – Hospitalisation still required for some patients: XDR, severe side-effects, late stage and/or severely ill, patients for whom am-
bulatory care is not feasible or not preferred
  – Children should also be diagnosed and treated
infection control:
  – Based on early diagnosis and effective treatment
  – Implementation of administrative, environmental and personnel protective measures
Psychosocial support: Individual and group education and counselling, defaulter tracing, incentives and enablers (such as reim-
bursement of patients’ transport costs, food parcels)
human resources: strong clinical supervision and training
drug supply management
XDR = extensively drug-resistant TB
box 2. MSF’s patient-centred model of careS. Healy et al.
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Specialised programs
While most programs provide services to the general 
population, two have focussed on specific populations. In 
Kyrgyzstan, TB is diagnosed and treated in the prison sys-
tem, a significant locus of infection throughout the East-
ern European and Central Asian region. The planned pro-
gram in Ukraine will also focus on prison populations. In 
Tajikistan, a paediatric TB program was started because 
TB in children had been neglected in this country, and 
indeed worldwide. There is a lack of appropriate TB drug 
formulations or diagnostic techniques available for chil-
dren, and few means of diagnosing or treating them for 
drug-resistant disease.
msf’s research
Programatic research
MSF has focused on documenting the scale of the prob-
lem (such as through involvement in two drug suscepti-
bility surveys with the Uzbek Ministry of Health in 2003 
and 2011), documenting the response to MDR-TB with 
international protocols and the limitations of these (for 
example, default rates in MDRTB [11]), and the wider 
issues that may influence program outcomes [12]. The 
foundation of MSF’s research in TB has been the de-
scription and analysis of its own cohorts and its expe-
riences in the introduction and implementation of par-
ticular technologies, e.g. GeneXpert in diagnosis. This 
research has two main aims. Firstly as part of routine 
monitoring and evaluation to ensure that treatment out-
comes and implementation meet required MSF as well as 
international standards. Secondly to propagate practices, 
technologies and models of care, in the hope that strong 
evidentiary backing will lead to them being adapted by 
other health providers. See Box 3 for examples of MSF 
research in MDR-TB.
Wider research issues
MSF clinicians and epidemiologists have also sought to 
investigate wider phenomena, including the causes of de-
fault, the incidence of XDR-TB and the availability of TB 
drugs outside the regulated market. Research is presently 
being conducted by anthropologists and health econo-
mists into the social and economic aspects of TB and the 
relevant aspects of health systems.
msf’s Public health advocacy
Why advocacy is essential
The numbers of patients within MSF programs is small 
compared with the numbers treated by Ministries of Health 
in the countries of the region, let alone compared with the 
numbers who are undiagnosed or untreated. Further, the 
success of control endeavours depends strongly on the ef-
fectiveness of available technologies. Therefore MSF en-
gages in public health advocacy with governments, inter-
national organisations, researchers and the pharmaceutical 
industry, in order to address the limitations in current prac-
tice and in the hope of mobilising wider efforts (Box 4).
Brust JC, Shah NS, Scott M, Chaiyachati K, Lygizos M, van der Merwe TL, Bamber S, Radebe Z, Loveday M, Moll AP, Margot 
B, Lalloo UG, Friedland GH, Gandhi NR: integrated, home-based treatment for mdr-tb and hiv in rural south africa: 
an alternate model of care. Int J Tuberc Lung Dis 16(8), 998–1004 (2012)
Cox HS, Kalon S, Allamuratova S, Siziare V, Tigay Z, Ruesch-Gerdes S, Karimovich K, Kebede Y, Mills C: multidrug-resist-
ant tuberculosis treatment outcomes in Karakalpakstan, uzbekistan: treatment complexity and Xdr-tb among 
treatment failures. PLoS ONE 2(11), e1126 (2007).
Lalor MK, Allamuratova S, Althomsons S, Tiegay Z, Khamraev AK, Grieg J, Braker K, du Cros P, Telnov O: risk factors asso-
ciated with default from multi drug resistant tuberculosis treatment, uzbekistan, in patients enrolled between 2003–
2008. Presentation at IUATLD conference (2011).
Majumdar S, O’Brien D, Hurtado N, Hewison C, du Cros P: the ‘frozen state’ of drug-resistant tuberculosis: notes from the 
field in abkhazia. Intern Med J 41, 805–808 (2011).
Cox HS, Kubica T, Doshetov D, Kabede Y, Ruesch-Gerdes S, Niemann S: the beijing genotype and drug resistant tuberculo-
sis in the aral sea region of central asia. Respir Res 6(1), 134 (2005) [13].
Bonnet M, Sizaire V, Kebede Y, Janin A, Doshetov D, Mirzoian B, Arzumanian A, Muminov T, Iona E, Rigouts L, Rüsch-Gerdes 
S, Varaine F: does one size fit all? drug resistance and standard treatments: results of six tuberculosis programmes in for-
mer soviet countries. Int J Tuberc Lung Dis 9(10), 1147–1154 (2005) [14].
Cox HS, Orozco JD, Male R, Ruesch-Gerdes S, Falzon D, Small I, Doshetov D, Kabede Y, Aziz M: multidrug-resistant tuber-
culosis in central asia. Emerg Infect Dis 10(5), 865–872 (2004) [15].
box 3. Examples of MSF’s research publications in MDR-TBEuropean Journal of Microbiology and Immunology 2 (2012) 4
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Partnerships
MSF’s principal partner is the Ministry of Health in the 
country it is working in. Many countries of the former So-
viet Union have been involved in (often difficult) reform 
processes within their health systems [16] and have been 
seeking to modernise their approaches to TB care. MSF 
has participated in review processes conducted by national 
health authorities for TB care strategies, protocols and 
prikaz (government regulations), with the aim of incorpo-
rating new technologies (such as rapid drug-susceptibility 
testing) and new approaches (such as Day 1 ambulatory 
treatment for MDR-TB patients) into government policy 
and practice. At the national and local levels, MSF has 
provided recommendations on implementation plans and 
strategies. MSF has also sought to encourage the exchange 
of experiences and practices between regional health of-
ficials through symposia, conferences and public reports.
Global efforts
In November 2011, the board of the Global Fund to fight 
AIDS, TB and Malaria cancelled its next scheduled 
funding round (‘Round 11’). Given that the Global Fund 
provides 82% [17] of external funding for TB, MSF is 
concerned that the decision could halt progress towards 
universal access to diagnosis and treatment. MSF has ad-
vocated the Global Fund implementing appropriate tran-
sitional measures to maintain existing national TB cohort 
sizes and donor countries maintaining previous commit-
ments to assist TB control efforts. The Global Fund in-
troduced a Transitional Funding Mechanism, which was 
a way of opening up funding requests for maintenance 
of current programs until the next round of funding is 
available in 2014/2015, but there is still considerable un-
certainty about the medium-term future of TB funding. 
MSF also seeks to share its experiences and work with 
global public health institutions, such as WHO, the Stop 
TB Partnership and the International Union against Tu-
berculosis and Lung Disease.
New technologies
While the availability of rapid drug-susceptibility tests is 
an important breakthrough for diagnosis, in the field of 
new treatments the pipeline has been empty for the past 40 
years [18]. Existing courses of treatment for MDR-TB have 
serious side-effects and are lengthy (at least 20 months), in 
large part because the drugs themselves are only weakly 
effective. The length and difficulty of treatment seems 
to be a major driver of high default rates. There are now 
some promising candidates for new drugs, including sev-
eral entering phase 3 trials [19]. MSF has long sought 
to accelerate this process through its Access Campaign, 
through advocacy efforts with the pharmaceutical indus-
try and with public–private partnerships for product de-
velopment. It seems unlikely that the MDR-TB epidemic 
can be contained without significant improvement in the 
technologies available, making treatment courses more 
effective, shorter, and easier to tolerate for the patient.
conclusion
Successful control of the epidemic in the region is still far 
away – and the Berlin and Beijing Declarations remain just 
that, declarations. Further, there is a question over whether 
the existing tools, especially the drugs available to treat 
MDR-TB, are successful enough to serve as the foundation 
for successful treatment programs of sufficient scale. So 
far, the international community has failed in its attempts 
to ensure access to effective, well tolerated treatment.
However, new opportunities need to be recognised. 
The advent of rapid drug susceptibility testing is a signifi-
cant step forward, addressing what was previously a major 
rate-limiting factor, the difficulty of quickly diagnosing 
drug resistance. Further, an international consensus is 
building in favour of innovative approaches to treatment, 
such as the new emphasis on ambulatory treatment, which 
may allow both scaled-up efforts and improved outcomes.
As a non-governmental medical-humanitarian associa-
tion, MSF will only ever have the resources to diagnose 
or treat a small number of cases. While the organisation 
sees its own direct efforts as a humanitarian necessity, it 
also sees the need for a wider mobilisation to universalise 
access to diagnosis and treatment. Indeed, MSF hopes that 
its experiences will help the adaption of new technologies 
and approaches, either constituting a ‘model’ for wider 
replication or serving as a catalyst for change. 
Organising symposia: 
Central Asian medical symposium, ‘Uniting to scale up TB care’. Tashkent, Uzbekistan, April 2011
Kyrgyzstan regional symposium planned for late 2012
Publication of reports:
Treating drug-resistant TB: what does it take?
Comprehensive TB Care for All: the Karakalpak Experience
Input into the drafting of Order 1224, by the Ministry of Health of the Republic of Chechnya, which provides the framework for 
TB diagnosis and treatment. December 2011
Input into the drafting of new infection control guidelines for all Ministry of Health TB facilities, in the Republic of 
Karakalpakstan, Uzbekistan
Developing a paediatric TB protocol for Tajikistan planned to be disseminated regionally through WHO
box 4. Examples of MSF’s advocacy in MDR-TBS. Healy et al.
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